In recent years, novel molecular oncology tests have been introduced to provide additional clinical information used in assessing an individual’s predisposition or lifetime risk of developing certain cancers. Molecular tests are also used to:

The Future of Cancer Diagnostics

BD Diagnostics - TriPath will eventually seek to market diagnostic tests that are currently in development.

Our ultimate goal is to change clinical practice, not laboratory practice. As such, all of our assays are being developed in commercially accepted formats to facilitate rapid laboratory adoption.

Our cancer screening and monitoring assay technologies are being formatted as immunoassay (IA) tests that are capable of detecting and quantifying multiple secreted markers (proteins) in blood.

Our staging and prognostic assay technologies will be slide-based utilizing tissue and cytology samples, and will allow for precise quantification of molecular markers (proteins) within the context of tissue and cellular morphology.

Though we will discuss our expectations for our molecular diagnostic products throughout the following section, there can be no assurance we will be successful in developing any products or services that will prove to have any clinical or therapeutic value to the healthcare system nor that we will be able to develop such tests in an economically viable way.